119 related articles for article (PubMed ID: 3309066)
1. Antibodies against synthetic carboxy-terminal peptides distinguish H-ras and K-ras oncogene products p21.
Ishihara H; Nakagawa H; Ono K; Fukuda A
J Immunol Methods; 1987 Oct; 103(1):131-9. PubMed ID: 3309066
[TBL] [Abstract][Full Text] [Related]
2. Characterization of monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma of v-Harvey-ras transgenic mouse.
Pullano TG; Sinn E; Carney WP
Oncogene; 1989 Aug; 4(8):1003-8. PubMed ID: 2474786
[TBL] [Abstract][Full Text] [Related]
3. Antibody of predetermined specificity to a carboxy-terminal region of H-ras gene products inhibits their guanine nucleotide-binding function.
Srivastava SK; Lacal JC; Reynolds SH; Aaronson SA
Mol Cell Biol; 1985 Nov; 5(11):3316-9. PubMed ID: 3915772
[TBL] [Abstract][Full Text] [Related]
4. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
[TBL] [Abstract][Full Text] [Related]
5. Antisera to the variable region of ras oncogene proteins, and specific detection of H-ras expression in an experimental model of chemical carcinogenesis.
Bizub D; Heimer EP; Felix A; Chizzonite R; Wood A; Skalka AM; Slater D; Aldrich TH; Furth ME
Oncogene; 1987 May; 1(2):131-42. PubMed ID: 2449645
[TBL] [Abstract][Full Text] [Related]
6. Presence and possible role of c-ras and nuclear (c-fos and c-jun) proto-oncogene products in preimplantation embryonic development in mice.
Ahmad K; Naz RK
Mol Reprod Dev; 1993 Nov; 36(3):297-306. PubMed ID: 8286110
[TBL] [Abstract][Full Text] [Related]
7. Preparation, characterization and properties of monoclonal antibodies against intact H-ras p21 proteins.
Sorrentino V; Nebreda AR; Alonso T; Santos E
Oncogene; 1989 Feb; 4(2):215-22. PubMed ID: 2467247
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to synthetic peptide from the residue 33 to 42 domain of c-Ha-ras p21 block reconstitution of the protein with different effectors.
Rey I; Soubigou P; Debussche L; David C; Morgat A; Bost PE; Mayaux JF; Tocque B
Mol Cell Biol; 1989 Sep; 9(9):3904-10. PubMed ID: 2550807
[TBL] [Abstract][Full Text] [Related]
9. Comparative immunohistochemical reactivity of monoclonal and polyclonal antibodies to H-ras p21 in normal and neoplastic tissues of rodents and humans.
Ward JM; Perantoni AO; Santos E
Oncogene; 1989 Feb; 4(2):203-13. PubMed ID: 2648257
[TBL] [Abstract][Full Text] [Related]
10. Purification of a fragment of MDM2 for production of polyclonal antisera.
Carstens BP; Perry ME
Protein Expr Purif; 2001 Mar; 21(2):361-5. PubMed ID: 11237699
[TBL] [Abstract][Full Text] [Related]
11. Detection of activated Mr 21,000 protein, the product of ras oncogenes, using antibodies with specificity for amino acid 12.
Wong G; Arnheim N; Clark R; McCabe P; Innis M; Aldwin L; Nitecki D; McCormick F
Cancer Res; 1986 Dec; 46(12 Pt 1):6029-33. PubMed ID: 3490906
[TBL] [Abstract][Full Text] [Related]
12. Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13.
La Vecchio JA; Hamer PJ; Ng SC; Trimpe KL; Carney WP
Oncogene; 1990 Aug; 5(8):1173-8. PubMed ID: 2202949
[TBL] [Abstract][Full Text] [Related]
13. Specific detection of the precursor of ras p21 with a mouse monoclonal anti-C-terminal peptide antibody, SARA-K1.
Ishihara H; Kimura M; Kuzumaki N; Ono K
J Immunol Methods; 1995 Sep; 185(2):217-23. PubMed ID: 7561132
[TBL] [Abstract][Full Text] [Related]
14. Production and characterization of monoclonal antibodies to Ha-ras and N-ras p21.
Ng S; Conlon J; Lavecchio J; Hamer PJ; Pullano T; Carney WP
Hybridoma; 1991 Aug; 10(4):467-80. PubMed ID: 1937497
[TBL] [Abstract][Full Text] [Related]
15. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
Peace DJ; Chen W; Nelson H; Cheever MA
J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
[TBL] [Abstract][Full Text] [Related]
16. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes.
Edwards RJ; Singleton AM; Murray BP; Davies DS; Boobis AR
Biochem Pharmacol; 1995 Jan; 49(1):39-47. PubMed ID: 7840781
[TBL] [Abstract][Full Text] [Related]
17. Organ specific expression of ras oncoproteins during growth and development of the rat.
Tanaka T; Ida N; Shimoda H; Waki C; Slamon DJ; Cline MJ
Mol Cell Biochem; 1986 Apr; 70(1):97-104. PubMed ID: 3520294
[TBL] [Abstract][Full Text] [Related]
18. Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding.
Clark R; Wong G; Arnheim N; Nitecki D; McCormick F
Proc Natl Acad Sci U S A; 1985 Aug; 82(16):5280-4. PubMed ID: 3927300
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody highly sensitive for the detection of ras p21 in immunoblotting analysis.
Kanai T; Hirohashi S; Noguchi M; Shimoyama Y; Shimosato Y; Noguchi S; Nishimura S; Abe O
Jpn J Cancer Res; 1987 Dec; 78(12):1314-8. PubMed ID: 3123435
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues.
Yang JL; Liu DX; Zhen SJ; Zhou YG; Zhang DJ; Yang LY; Chen HB; Feng Q
BMC Cancer; 2016 Feb; 16():131. PubMed ID: 26897358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
